Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

improved, unchanged and worsened by 64.3%, 21.4% and 14.3%, respectively. The EDSS for a 0.5 point sustained (no change over 3 months) effect was improved, unchanged and worsened by 42.9%, 42.9% and 14.2%, respectively. The EDSS for a 1.0 sustained effect was improved, unchanged and worsened by 28.6%, 57.1% and 14.3%, respectively.

Brian Loftus, M.D. of Bellaire Neurology, the Principal Investigator of these Tovaxin studies, commented, "This data, combined with prior data presented on myelin reactive T-cell frequencies and ARR reductions, laid the ground work for the placebo-controlled Tovaxin IIb clinical trial (TERMS). We have shown that myelin reactive T-cells can be identified and used to produce T-cell vaccine which effectively induces the depletion of an individual's autoreactive T-cells and results in positive clinical outcomes. I anticipate Tovaxin will usher in the age of personalized therapy for MS."

David McWilliams, president and chief executive officer of Opexa, said, "We are particularly encouraged by the data from this extension trial which indicates that subjects previously treated with T-cell vaccine can be safely and effectively retreated with Tovaxin. This outcome is important to our planned extension trial for subjects currently enrolled in our TERMS trial following the one year core study time period." In addition, the effectiveness data in RRMS subjects across the two Phase I/II trials indicate strongly positive outcomes in both ARR and EDSS improvements following Tovaxin therapy."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T-cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-ar
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:8/27/2015)... 2015 According to a new ... (Integrated, Standalone), by Deployment Mode (Web based, On-Premise, Cloud-Based), ... Service Providers), by Component - Global Trends & Forecast ... estimated at $501.1 Million 2014, and is projected to ... 7.6% from 2014 to 2019. Browse ...
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... YORK , Aug. 27, 2015   Americord ... cord tissue , and placenta tissue banking ... cord blood banking e-commerce website. This new website makes ... ever with an interactive shopping cart and checkout process. ... "Most cord blood banking websites make this service ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... PhotoMedex, Inc. (Nasdaq: PHMD ) announced ... current clinical trial being performed by John Y.M. Koo, ... of California, San Francisco. Dr. Koo,s experimental treatment protocol ... from moderate to severe psoriasis. The study, which utilizes ...
... Awarepoint Corporation announced today that CEO Jay Deady will ... Healthcare Innovation Summit on April 14, 10:30 a.m. – ... York. Joining Deady on the panel will be Harry Greenspun, ... Safavi, M.D., vice president and global lead of the Cisco ...
Cached Medicine Technology:Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 2Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers 3Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 2Awarepoint CEO Jay Deady to Serve as Panelist at IBF's Digital Healthcare Innovation Summit 3
(Date:8/27/2015)... ... August 27, 2015 , ... Workflow in labs has greatly ... in the last decade. New features such as multiplexing, microfluidics, and integration ... where do lab managers, technicians, and researchers find handy metrics to compare and ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... According ... and the American Heart Association have released new guidelines to educate doctors and patients ... last update to these particular guidelines came in 2007, so the new version is ...
(Date:8/27/2015)... ... 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney ... in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. ... health authorities, and will present a two part seminar entitled, “How to Thrive as ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... exploding legal marijuana industry with the launch of its Doobster platform, a HIPAA-compliant ... to order products from their smart phones and tablets. Well, Doobster, “The ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... Hurricane Katrina slammed into the Gulf Coast, killing more than 1,800 people, displacing ... according to a Georgia State University study. , While most people don’t develop ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2
... change habits, but social shame works even better, suggests a ... disease rates blamed on the microbial pathogens that cause diarrhea ... workers there just beating their heads against the reality of ... to change it," said Subhrendu Pattanayak, an associate professor at ...
... Unlike other forms of suicide, physician assisted death does ... among surviving family members. In addition, the prevalence and ... loved ones received aid in dying is no different ... physician assisted suicide. These findings are the result of ...
... ... Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from ... ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits ...
... researchers , WEDNESDAY, Sept. 30 (HealthDay News) -- Non-AIDS-related ... more common among HIV patients than among people without ... to treat people with the virus, U.S. researchers say. ... are at increased risk for so-called AIDS-defining malignancies, which ...
... to 49 are 19 times more likely to have memory ... Former professional football players suffer from Alzheimer,s disease or other ... a new study commissioned by the National Football League shows. ... 49 are 19 times more likely to struggle with memory ...
... ... selected Water For People to provide technical support for a 31-million-euro initiative funded by ... drinking water and improved sanitation to more than 540,000 people in 21 low-income areas ... ...
Cached Medicine News:Health News:Peer pressure builds more latrines than financial assistance 2Health News:Peer pressure builds more latrines than financial assistance 3Health News:Physician-assisted suicide does not increase severity of depression, grief among family members 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Health News:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Health News:Non-AIDS-Related Cancers Growing Among HIV Patients 2Health News:Dementia Risk Higher for NFL Players 2Health News:Dementia Risk Higher for NFL Players 3Health News:Dementia Risk Higher for NFL Players 4Health News:Dementia Risk Higher for NFL Players 5Health News:Dementia Risk Higher for NFL Players 6Health News:Water For People Selected for $1.56 Million Project in Africa 2Health News:Water For People Selected for $1.56 Million Project in Africa 3Health News:Water For People Selected for $1.56 Million Project in Africa 4
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
Portable shields for your safety and convenience....
Medicine Products: